Personalized ayurvedic approach involving Sadyo Vamana in COVID-19 management: A case report.

Sars Cov-2 has emerged as a global threat worldwide. At present, India is the second worsely-hit nation by COVID-19. Since it is a novel virus, there is no specific treatment strategy available at present. A mild symptomatic case of COVID-19 was managed through Ayurvedic intervention involving a personalized approach based on his Prakruti. He was prescribed Vamana Karma followed by Vyaghryadi Kashaya as an oral drug for fifteen days. The patient recovered well clinically, the disease progression to a more severe stage was not observed and the patient tested negative for COVID on the 17th day. In this report, the patient was of Kapha predominant Prakruti and his strength was good so he was prescribed Vamana Karma. Ayurveda advocates patient management by incorporating personal physical and mental attributes classified as Doshas. The promising results in the present case study indicate that a personalized approach involving Ayurveda in such cases can be helpful for a better prognosis.

A randomized open label parallel group pilot study to evaluate efficacy of Ayurveda interventions in the management of asymptomatic and mild COVID-19 patients-experiences of a Lucknow based level 2 hospital of Uttar Pradesh, India.

BACKGROUND: SARS--CoV-2 has emerged as a global threat since its onset in December 2019. India has also been severely affected by the dreadful Corona Virus and is currently battling one of the worst pandemics of history. WHO and the world medical fraternity are putting their efforts to materialize a treatment or vaccine for this novel virus. A randomized open label parallel group study was designed in a Lucknow based level 2 COVID hospital to evaluate the efficacy of Ayurvedic interventions in the management of asymptomatic and mild COVID 19 patients. OBJECTIVE: To evaluate the efficacy of Ayurveda in the management of mildly affected COVID-19 patients. MATERIALS AND METHODS: The current trial was an open label randomized 10-day study. Total 120 asymptomatic and/or mild COVID-19 positive patients fulfilling inclusion criteria were randomly grouped into three. RT-PCR of all the patients were done on 5th, 7th and on 10th day respectively. The observations were noted and results were analyzed statistically. Kruskal-Wallis test and Wilcoxon Sign rank test were used for data analysis where applicable. RESULTS: Improvement in symptoms, enhancement in Agni and recovery from COVID infection was observed. The results obtained were encouraging and showed better viral clearance and control of symptom progression in the patients placed on Ayurvedic medications. CONCLUSION: The promising results in the study showed that an approach involving Ayurveda can be helpful for the management of the mild COVID-19 patients. Ayurveda can be used to limit community spread and check disease progression to a more appalling state. TRIAL REGISTRATION: Trial was registered with Clinical Trials Registry- India (CTRI registration number: CTRI/2020/06/025800.

In vitro and in vivo antidiabetic effect of extracts of Melia azedarach, Zanthoxylum alatum, and Tanacetum nubigenum.

BACKGROUND: To investigate the antidiabetic effect of Himalayan Medicinal plants from India viz. Melia azedarach (Family: Meliaceae), Zanthoxylum alatum (Family: Rutaceae), Tanacetum nubigenum (Family: Asteraceae) using in-vitro as well as in-vivo approaches. METHODS: Their effects were examined on stimulation of glucose uptake by C2C12 cultured cell line, inhibitory effect on human recombinant Protein tyrosine phosphatase-1B (PTP-1B) and followed by the hypoglycaemic activity of extracts in Streptozotocin (STZ) induced diabetic rats. RESULTS: All prepared extracts had been found to enrich with polyphenolic, flavonoids, terpenoids, anthraquinones and saponins type of compounds. n-Butanol fraction of Zanthoxylum alatum showed maximum PTP-1B inhibition (61.9%) whereas ethanol extract of Tanacetum nubigenum showed strong stimulation of glucose uptake (+61.2%) in C2Cl2 myotubes. In STZ induced Sprague-Dawley rats, significant decrease in blood glucose level was observed in ethanol extract of Melia azaderach treated group as 14.8% (p < 0.01) whereas in the ethanol extract of Tanacetum nubigenum treated group, it was observed as 15.5% (p < 0.01) compare to metformin which showed 26.8% (p < 0.01) lowering of blood glucose in the same time duration of 5 h study. CONCLUSION: This study demonstrated that these plants have a significant therapeutic value in type-2-diabetes mellitus and related complications thus supporting their traditional uses in Indian traditional system of medicine.

Lycopene and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis.

Prostate cancer (PCa) is a common illness for aging males. Lycopene has been identified as an antioxidant agent with potential anticancer properties. Studies investigating the relation between lycopene and PCa risk have produced inconsistent results. This study aims to determine dietary lycopene consumption/circulating concentration and any potential dose-response associations with the risk of PCa. Eligible studies published in English up to April 10, 2014, were searched and identified from Pubmed, Sciencedirect Online, Wiley online library databases and hand searching. The STATA (version 12.0) was applied to process the dose-response meta-analysis. Random effects models were used to calculate pooled relative risks (RRs) and 95% confidence intervals (CIs) and to incorporate variation between studies. The linear and nonlinear dose-response relations were evaluated with data from categories of lycopene consumption/circulating concentrations. Twenty-six studies were included with 17,517 cases of PCa reported from 563,299 participants. Although inverse association between lycopene consumption and PCa risk was not found in all studies, there was a trend that with higher lycopene intake, there was reduced incidence of PCa (P = 0.078). Removal of one Chinese study in sensitivity analysis, or recalculation using data from only high-quality studies for subgroup analysis, indicated that higher lycopene consumption significantly lowered PCa risk. Furthermore, our dose-response meta-analysis demonstrated that higher lycopene consumption was linearly associated with a reduced risk of PCa with a threshold between 9 and 21 mg/day. Consistently, higher circulating lycopene levels significantly reduced the risk of PCa. Interestingly, the concentration of circulating lycopene between 2.17 and 85 µg/dL was linearly inversed with PCa risk whereas there was no linear association >85 µg/dL. In addition, greater efficacy for the circulating lycopene concentration on preventing PCa was found for studies with high quality, follow-up >10 years and where results were adjusted by the age or the body mass index. In conclusion, our novel data demonstrates that higher lycopene consumption/circulating concentration is associated with a lower risk of PCa. However, further studies are required to determine the mechanism by which lycopene reduces the risk of PCa and if there are other factors in tomato products that might potentially decrease PCa risk and progression.

Bioactivity-guided chemical analysis of Melia azedarach L. (Meliaceae), displaying antidiabetic activity.

One new Euphane-type triterpenoid 3ß-hydroxytirucalla-5, 24-dien-21-oic acid (1), and ten known compounds (2-11) were isolated from Melia azedarach L. through bioassay-guided chemical analysis. The structures of the isolated compounds were established by means of 1D and 2D NMR spectroscopic ((1)H, (13)C, DEPT, COSY, HSQC and HMBC) and MS spectral analyses. All the fractions and isolated pure compounds were evaluated for antidiabetic activity by determining their inhibitory effects on PTP-1B enzyme as well as glucose uptake stimulation in C2Cl2 myoblasts cells. Compounds 4 and 7 showed significant in vitro PTP-1B inhibitory activity with 69.2 and 66.8% inhibition at 10 µg/ml concentrations respectively.

Bioactive flavanoids from Glycosmis arborea.

BACKGROUND: Glycosmis is a genus of evergreen glabrous shrub and distributed all over India. It possesses various medicinal properties and is used in indigenous medicine for cough, rheumatism, anemia, and jaundice. Glycosmis arborea is a rich source of alkaloids, terpenoids, coumarins, as well as flavonoids. RESULTS: The chemical investigation of methanol fraction of the leaves of G. arborea led to the isolation of one new flavone C-glycoside along with three known flavanoids, named as 5,7-dihydroxy-2-[4-hydroxy-3-(methoxy methyl) phenyl]-6-C-ß-d-glucopyranosyl flavone (4), 5,7,4'-trihydroxy-3'-methoxy flavone (1), 5,4'-dihydroxy-3'-methoxy-7-O-ß-d-glucupyranosyl flavanone (2), and 5,4'-dihydroxy-3'-methoxy-7-O-(α-l-rhamnosyl-(1‴→6‴)-ß-d-glucopyranosyl) flavanone (3), respectively. The structures of all compounds were elucidated with the help of nuclear magnetic resonance spectrometry. Pure compounds and fractions were evaluated for pest antifeedant and antimicrobial activity. CONCLUSION: Four compounds were isolated from the leaves of G. arborea. Among them, compound 4 showed significant antimicrobial activity.

(±)-Asarinin.

Asarinin, C(20)H(18)O(6), was isolated as a racemate from the shrub Zanthoxylum alatum. Both forms of the enantiomerically pure substance, (+)- and (-)-asarinin, have been the subject of a total of five previous structure determinations that are essentially identical except for the absolute stereochemistry. However, there seems to be some confusion in the literature concerning these structure determinations of asarinin and also those of its stereoisomer sesamin. The molecular structure of racemic asarinin differs from that of the pure enantiomers in the orientation of one ring system. In the packing of the racemate, molecules are linked by C-H...O interactions to form ribbons parallel to [101].

A condensed phenylpropanoid glucoside and pregnane saponins from the roots of Hemidesmus indicus.

From the roots of Hemidesmus indicus, one new condensed phenylpropanoid glucoside and three new pregnenolone glycosides, named hemidesmosides A-C, were isolated along with one known related compound, plocoside A.

Chemical and antibacterial constituents of Skimmia anquetelia.

Investigation of the leaves of Skimmia anquetelia (Rutaceae) led to the isolation of a new coumarin glucoside 7,8-dihdroxy-6-[3'-beta- D-glucopyranosyloxy-2'(xi)-hydroxy-3'-methylbutyl]-coumarin ( 1) together with five known coumarins: 6-(2,3-dihydroxy-3-methylbutyl)-7-methoxycoumarin ( 2), skimmin ( 3), osthol ( 4), esculetin ( 5) and scopuletin ( 6). The antibacterial activity of compounds 1 and 3 was also investigated against the plant bacterial pathogens Agrobacterium tumifaciens, Pseudomonas syringae and Pactobacterium carotovorum. Structures were determined on the basis of analyses of spectral evidence including 1D, 2 D NMR (COSY, HMQC, HMBC and NOESY) and mass spectroscopy.